Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Cell Line Development: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Cell Line Development estimated at US$7.5 Billion in the year 2022, is projected to reach a revised size of US$14.7 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2022-2030. Reagents & Media, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$8.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Equipment segment is readjusted to a revised 8.4% CAGR for the next 8-year period. 
The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 8.2% CAGR
The Cell Line Development market in the U.S. is estimated at US$2.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.2% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
Select Competitors (Total 44 Featured) -
- Abzena PLC
- American Type Culture Collection (ATCC)
- Apath LLC
- Bioceros
- Catalent, Inc.
- CELLforCURE
- Cobra Biologics
- Corning, Inc.
- Cyagen US Inc.
- Cytovance Biologics
- Epistem Holdings PLC
- EuBiologics Co., Ltd.
- GE Healthcare
- GVK Biosciences Private Limited
- Hitachi Chemical Advanced Therapeutics Solutions, LLC
- Lonza Group Ltd.
- MilliporeSigma
- NAEJA-RGM Pharmaceuticals, Inc.
- Paragon Bioservices, Inc.
- Patheon, Inc.
- Promocell GmbH
- Samsung BioLogics
- Sartorius AG
- Selexis SA
- Thermo Fisher Scientific, Inc.
- WuXi AppTec
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 193 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $7.5 Billion |
| Forecasted Market Value (USD) by 2030 | $14.7 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes
- Abzena PLC
- American Type Culture Collection (ATCC)
- Apath LLC
- Bioceros
- Catalent, Inc.
- CELLforCURE
- Cobra Biologics
- Corning, Inc.
- Cyagen US Inc.
- Cytovance Biologics
- Epistem Holdings PLC
- EuBiologics Co., Ltd.
- GE Healthcare
- GVK Biosciences Private Limited
- Hitachi Chemical Advanced Therapeutics Solutions, LLC
- Lonza Group Ltd.
- MilliporeSigma
- NAEJA-RGM Pharmaceuticals, Inc.
- Paragon Bioservices, Inc.
- Patheon, Inc.
- Promocell GmbH
- Samsung BioLogics
- Sartorius AG
- Selexis SA
- Thermo Fisher Scientific, Inc.
- WuXi AppTec
For more information about this report visit https://www.researchandmarkets.com/r/3j8qqm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
